NASDAQ:SRRA - Sierra Oncology Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $1.94 +0.07 (+3.74 %) (As of 10/18/2018 01:41 AM ET)Previous Close$1.87Today's Range$1.81 - $1.9452-Week Range$1.48 - $4.09Volume1.68 million shsAverage Volume548,270 shsMarket Capitalization$126.39 millionP/E Ratio-2.31Dividend YieldN/ABeta2.18 Company ProfileDiscussionAnalyst RatingsChartEarnings HistoryFinancialsInsider TradesHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Sierra Oncology, Inc., a clinical stage drug development company, researches, develops, and commercializes DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer in the United States and internationally. The company's lead drug candidate is SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1, which is in Phase 1 clinical trial to treat patients with advanced cancer. It also engages in developing SRA141, an orally bioavailable small molecule inhibitor of the cell division cycle 7 kinase that is in preclinical development stage. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was founded in 2003 and is headquartered in Vancouver, Canada. Receive SRRA News and Ratings via Email Sign-up to receive the latest news and ratings for SRRA and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:SRRA CUSIPN/A Webwww.sierraoncology.com Phone604-558-6536 Debt Debt-to-Equity RatioN/A Current Ratio16.20 Quick Ratio16.20 Price-To-Earnings Trailing P/E Ratio-2.31 Forward P/E Ratio-2.73 P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book Value$1.81 per share Price / Book1.07 Profitability EPS (Most Recent Fiscal Year)($0.84) Net Income$-42,010,000.00 Net MarginsN/A Return on Equity-39.19% Return on Assets-36.95% Miscellaneous Employees57 Outstanding Shares74,340,000Market Cap$126.39 million Sierra Oncology (NASDAQ:SRRA) Frequently Asked Questions What is Sierra Oncology's stock symbol? Sierra Oncology trades on the NASDAQ under the ticker symbol "SRRA." How were Sierra Oncology's earnings last quarter? Sierra Oncology Inc (NASDAQ:SRRA) released its quarterly earnings results on Thursday, August, 9th. The biotechnology company reported ($0.16) EPS for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.16). View Sierra Oncology's Earnings History. When is Sierra Oncology's next earnings date? Sierra Oncology is scheduled to release their next quarterly earnings announcement on Wednesday, November 14th 2018. View Earnings Estimates for Sierra Oncology. What is the consensus analysts' recommendation for Sierra Oncology? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sierra Oncology in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sierra Oncology. Who are some of Sierra Oncology's key competitors? Some companies that are related to Sierra Oncology include Akebia Therapeutics (AKBA), Zymeworks (ZYME), Evolus (EOLS), Five Prime Therapeutics (FPRX), Collegium Pharmaceutical (COLL), Minerva Neurosciences (NERV), Progenics Pharmaceuticals (PGNX), Kindred Biosciences (KIN), TG Therapeutics (TGTX), Forty Seven (FTSV), Depomed (DEPO), Dermira (DERM), ZIOPHARM Oncology (ZIOP), Aclaris Therapeutics (ACRS) and Merus (MRUS). Who are Sierra Oncology's key executives? Sierra Oncology's management team includes the folowing people: Dr. Nicholas R. Glover, Pres, CEO & Director (Age 49)Dr. Barbara Klencke, Chief Devel. Officer (Age 61)Dr. Mark M. Kowalski, Chief Medical Officer (Age 63)Mr. Sukhi Jagpal CA, CPA, CBV, MBA, Chief Financial Officer (Age 44)Dr. Keith E. Anderson Ph.D., Sr. VP of Technical Operations (Age 49) How do I buy shares of Sierra Oncology? Shares of SRRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Sierra Oncology's stock price today? One share of SRRA stock can currently be purchased for approximately $1.94. How big of a company is Sierra Oncology? Sierra Oncology has a market capitalization of $126.39 million. The biotechnology company earns $-42,010,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis. Sierra Oncology employs 57 workers across the globe. What is Sierra Oncology's official website? The official website for Sierra Oncology is http://www.sierraoncology.com. How can I contact Sierra Oncology? Sierra Oncology's mailing address is 2150 -885 WEST GEORGIA STREET, VANCOUVER A1, V6C 3E8. The biotechnology company can be reached via phone at 604-558-6536 or via email at [email protected] MarketBeat Community Rating for Sierra Oncology (NASDAQ SRRA)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 174 (Vote Outperform)Underperform Votes: 158 (Vote Underperform)Total Votes: 332MarketBeat's community ratings are surveys of what our community members think about Sierra Oncology and other stocks. Vote "Outperform" if you believe SRRA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SRRA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 10/18/2018 by MarketBeat.com StaffFeatured Article: What is the 52-week high/low?